Rev. 2-88)	ORMATION DISCLO BY APPLI	EMENT	APPLICANT JACKOWSKI et					
10 2002 g	(Use several sheets	if necessary)	necessary)		12/13/01		1645 1647	
3		U.S. PA1	TENT DOCUMENTS					
BANELAS BRITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCL		IG DATE ROPRIATE
y C	5,062,935	11/91	Schlag et al.					
LYC	6,020,208	02/00	Hutchens et al.					
					_	<u> </u>		
							REC	
						<u> </u>	APR 2	9 20
						TFO	CH CENT	
			<u> </u>				DE WILL	בח וסט
		ļ				ļ		
						 		
				1	<u> </u>	<u></u>		
	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANS YES	NO
LYC	WO 93/24834	12/93	PCT				X	""
	WO 90/14148	11/90	PCT				х	
	WO 98/07036	02/98	PCT	Ì				×
LYC	WO 98/07036	02/98	PCT (translation)				×	
	OTHER DOCUM	ENTS (Including	Author, Title, Date, I	Pertinent	Pages, Et	rc.)		
k			Sensitive Immunoassa Ional Antibody", Clini					
VC		Richter et al., "Composition of the peptide fraction in human blood plasma: database of circulating human peptides", Journal of Chromatography B; 726 (1999) pp. 25-35.						
MINER O	isa. L Cook		DATE CONSIDERED	/	24/04	/		

RECEIVED

APR 1 5 2002

Form PTO-14	149		. DEPARTMENT OF COMMERCE TENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. 2132.089		APPLICA	net 1 ATION NO. 020,00	<u>of 1</u> 8
The second second	ORMATION DISCLOS BY APPLIC		EMENT	APPLICANT JACKOWS	SKI et al.			
& IRAE ZALTE	(Use several sheets	if necessary)		FILING DATE 12/13/01	-	164	<i>I</i>	
		U.S. PA	TENT DOCUMENTS					
EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CL	ASS F	活		DATE
							751	VE
						MA	02	200
					TECH	CEA	TED	
						- M-L	/ E/ }(300/
		 					· · - · - ·	
		 		+				
		 	ļ					
					_			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCL	ASS	TRANSLA	Т
LVC_	WO 02/21227	06/00	PCT				YES X	NO
1	WO 93/31227	06/99		-				t
LYC	WO 00/49410	08/00	PCT				X	
40	WO 01/05422	01/01	PCT				-	X
	OTHER DOCUME	NTS (Including	g Author, Title, Date,	Pertinent Page	s. Etc.)			1
LVC	Merched, et al.	., "Cerebrospir	nal fluid apolipoprotein ences (1997) Vol. 145	E level is incre	eased in la	te-onse	et Alzheir	mer's
LYC		t follow up an	fluid apolipoprotein E (d show a correlation v 2, pp. 85-88.					

 EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEP 2 8 2003 & SEP 2 9 2003 & SEP 2

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0301

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ans are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Complete if Known

Application Number 10/020,008

Filing Date 12/13/2001

First Named Inventor George Jackowski CA

Art Unit 1645 (C4)

Examiner Name L. Cook

2132.089

U. S. PATENT DOCUMENTS Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Wh Initials* MM-DD-YYYY Applicant of Cited Document Relevant Passages or Releva Number-Kind Code^{2 (F trous)} Figures Appear ^{US-} 5,759,816 UC 06/02/1998 A. Oppenheim ^{US-} 5,583,201 12/10/1996 B. Cameron WC US US-115. US-US-US-US-US-US-US-US-US-US US-US-US-US-

Attorney Docket Number

	FOREIGN PATENT DOCUMENTS							
Examiner Cite Initials* No.1		Foreign Patent Document	n Patent Document Publication Nan Date Applicat		Pages, Columns, Lines, Where Relevant Passages	Π		
		Country Code ³ Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear			
LYC,		WO99/31227	06/24/1999	Univ Western Ontario				
		WO01/75454	10/11/2001	Oxford Glycosciences				
		WO01/63294	08/30/2001	Oxford Glycosciences				
		WO02/059604	08/01/2002	Oxford Glycosciences				
		WO02/088750	11/07/2002	Oxford Glycosciences				
LYC		WO93/15198	08/05/1993	Rhone-Poulenc Rorer				

Examiner Signature Oficia. I Cook Date Considered 12/24/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is statched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Sheet



Under the Paperwork Reduction Ac

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

(Use as many sheets as necessary)

of

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ire required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

Application Number 10/020,008

12/13/2001

George Jackowski

			U. S. PATENT D	DCUMENTS		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan	
		Number-Kind Code ^{2 (F known)}			Figures Appear	
		US-				
	/	US-				
		US-				
		MS-				
		US-				
		US-		· · · · · · · · · · · · · · · · · · ·		
		US-				
		US-		.		
		US				
		US-				
		US-				
		US-				
		US-		<u> </u>		
		US-	 			
		US-				
		US-	 			
		US-				
	\neg	US-		*		
		US-	+		 \	

		FORE	IGN PATENT DOC	JMENTS		-
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁸ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T
LYC		WO01/77124	10/18/2001	Genaissance Pharm.		
LYC		WO01/75177	10/11/2001	Government of USA		
				as represented by		
				The Secretary, Dept		
				Health & Human Serv.		
						Г

Examiner Data Risa. 12/24 04 Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usgto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

SEP 2 9 2003 & Sep 2

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it contains a valid OMB control number.

Compl te if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

3

3

Sheet

	Compi të li Known	1
Application Number	10/020,008	
Filing Date	12/13/2001	₹
First Named Inventor	George Jackowski	
Art Unit	1645 1641	2 3
Examiner Name	L. Cook	7C2 1
Attorney Docket Number	2132.089	This day
		1/2
NT LITERATURE DOC	UMENTS	

		NON PATENT LITERATURE DOCUMENTS	00		
Examiner Initials*	Cite No.1				
WC		J. SILKENSEN et al, "Identification of clusterin sequences mediating renal tubular cell interactions", J. Peptide Res., 54(5):449-457 (November, 1999)			
		A. CSASZAR et al, "Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease", Neuroscience Letters, 230(3):151-154 (1997)			
		S. HARR et al, "Brain Expression of Apolipoproteins E, J, and A-I in Alzheimer's Disease", J. Neurochem., 66(6):2429-2435 (1996)			
		B. VERGES et al, "Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM", Diabetes, 46(1):125-132 (January, 1997)			
		P. WONG et al, "Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration", Eur. J. Biochem., 221(3):917-925 (1994)			
		N. DEMEESTER et al, "Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease", J. Lipid Res., 41(6):963-974 (June, 2000)			
		R. STEWART, "Cardiovascular factors in Alzheimer's disease", J. Neurol. Neurosurg. Psychiatry, 65(2):143-147 (1998)			
LVC		J. SLEMMON et al, "Profiling of endogenous peptides as a tool for studying development and neurological disease", Biopolymers, 43(2):157-170 (1997)			

Examiner Signature	Kisa)	l Cook	Date Considered	12/24/04

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.